RNTX on Nasdaq

Rein Therapeutics, Inc.

We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerRNTX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersAustin, Texas1
  • Business address12407 N. Mopac Expy., Suite 250 #390, Austin, Tx 787582
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, however, due to insufficient funding we have paused development of LTI‑01 for an undetermined period of time and are prioritizing LTI‑03. Our pipeline includes:3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-294.8%Return on equity4

Financial statements

Revenue567894$0 in 2025
02019: $0$020192020: $0$020202021: $0$020212022: $0$020222023: $0$020232024: $0$020242025: $0$02025
Operating income567894-$50.6M in 2025+69% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$30.0M-$30.0M20192020: -$20.5M-$20.5M2020−32%2021: -$26.6M-$26.6M2021+30%2022: -$27.6M-$27.6M2022+4%2023: -$16.3M-$16.3M2023−41%2024: -$65.1M-$65.1M2024+300%2025: -$50.6M-$50.6M2025−22%
Net income57894-$49.9M in 2025+70% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$29.4M-$29.4M20192020: -$27.3M-$27.3M2020−7%2021: -$26.2M-$26.2M2021−4%2022: -$27.3M-$27.3M2022+4%2023: -$15.7M-$15.7M2023−42%2024: -$62.9M-$62.9M2024+300%2025: -$49.9M-$49.9M2025−21%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenue$0$0
Research and development$11.0M$14.2M
General and administrative$10.9M$13.9M
Impairment loss on intangible assets$28.7M$37.0M
Total operating expenses$50.6M$65.1M
Loss from operations-$50.6M-$65.1M
Other income, net$48.0K$685.0K
Income tax benefit$712.0K$1.5M
Net loss-$49.9M-$62.9M
Net loss per share - basic-$1.96-$3.51
Net loss per share - diluted-$1.96-$3.51
Weighted average common shares outstanding - basic25.4M shares17.9M shares
Weighted average common shares outstanding - diluted25.4M shares17.9M shares
Unrealized (loss) gain on investments, net of tax of $0-$15.0K$45.0K
Foreign currency translation adjustments-$29.0K$0
Total other comprehensive (loss) gain-$44.0K$45.0K
Total comprehensive loss-$49.9M-$62.8M
Unrealized gain on investments, tax$0$0

Compare Rein Therapeutics, Inc. with another company

Leadership

Who has led Rein Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. John P. Longenecker Phd.2018
  2. Manuel Aivado2018–2019
  3. James Brian Windsor2024–now

President

  1. John P. Longenecker Phd.2018
  2. Manuel Aivado2018–2019
  3. James Brian Windsor2023–now

Chief financial officer

  1. Donald Dougherty2017–2019

Chief operating officer

  1. James Brian Windsor2023–2024
20202025
Board members and other officers (28)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerBrian L. Windsor, Ph.D. named Nov 16, 202343
  • Executive Officer, DirectorManuel Alves-Aivado, M.D., Ph.D. named Nov 16, 202343
  • DirectorJosef H. von Rickenbach named Nov 16, 202343
  • DirectorNolan H. Sigal, M.D., Ph.D. named Nov 16, 202343

Former names

  • Aileron Therapeutics, Inc.Apr 1, 2024 to Dec 9, 20242
  • AILERON THERAPEUTICS INCDec 3, 2007 to Mar 29, 20242

Timeline

  1. Dec 4, 2024New chief executive James Brian Windsor becomes CEO12
  2. Sep 7, 2018New chief executive Manuel Aivado becomes CEO14
  3. May 17, 2018New chief executive John P. Longenecker Phd. becomes CEO13

Filings

214 filings to the SEC since October 2021: 9 annual reports, 15 quarterly reports, 53 major events, 57 insider forms, 22 large holders, 1 private raises, 57 other. The latest 20:

  1. Sep 4, 20268-K EDGAR
  2. Aug 27, 20268-K EDGAR
  3. Aug 14, 202610-Q EDGAR
  4. Aug 14, 2026SCHEDULE 13G EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Aug 13, 2026SCHEDULE 13G/A EDGAR
  7. Jul 21, 20268-K EDGAR
  8. Jul 14, 2026SCHEDULE 13G/A EDGAR
  9. Jun 8, 2026ARS EDGAR
  10. Jun 8, 2026DEFA14A EDGAR
  11. Jun 8, 2026DEF 14A EDGAR
  12. May 28, 20264 EDGAR
  13. May 28, 2026PRE 14A EDGAR
  14. May 15, 202610-Q EDGAR
  15. May 13, 20264 EDGAR
  16. May 8, 2026SCHEDULE 13G/A EDGAR
  17. May 8, 2026SCHEDULE 13G EDGAR
  18. May 7, 2026SCHEDULE 13G EDGAR
  19. May 6, 2026SCHEDULE 13G EDGAR
  20. May 4, 20268-K EDGAR

The 214 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

24 open-market trades by officers, directors and large owners since October 2021: 12 buys and 12 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 27, 2026VON RICKENBACH JOSEF HDirectorBuy4,500$1.07$4.8KForm 4
May 26, 2026VON RICKENBACH JOSEF HDirectorBuy23,190$1.06$24.6KForm 4
May 22, 2026VON RICKENBACH JOSEF HDirectorBuy15,950$1.05$16.7KForm 4
May 21, 2026VON RICKENBACH JOSEF HDirectorBuy3,420$1.04$3.6KForm 4
Apr 30, 2026WINDSOR JAMES BRIANSee RemarksBuy25,000$1.00$25.0KForm 4
Nov 14, 2025Voss Value Master Fund, LP10% ownerBuy104,183$1.22$127.1KForm 4
Oct 28, 2025Voss Value-Oriented Special Situations Fund, LP10% ownerBuy178,392$1.39$248.0KForm 4
Oct 27, 2025Voss Value-Oriented Special Situations Fund, LP10% ownerBuy97,482$1.37$133.6KForm 4
Oct 24, 2025Voss Value-Oriented Special Situations Fund, LP10% ownerBuy30,176$1.39$41.9KForm 4
Dec 5, 2024WINDSOR JAMES BRIANSee RemarksBuy400$2.24$898Form 4
Jun 17, 2024UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% ownerSale4,707$3.25$15.3KForm 4
Jun 14, 2024UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% ownerSale1,900$3.30$6.3KForm 4
Jun 12, 2024UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% ownerSale9,342$3.25$30.4KForm 4
Jun 11, 2024UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% ownerSale5,752$3.26$18.7KForm 4
Jun 10, 2024UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% ownerSale9,577$3.30$31.6KForm 4
Jun 7, 2024UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% ownerSale1,740$3.26$5.7KForm 4
Jun 6, 2024UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% ownerSale4,284$3.29$14.1KForm 4
Jun 5, 2024UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% ownerSale6,291$3.30$20.8KForm 4
May 1, 2024UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% ownerSale20,315$4.21$85.5KForm 4
May 1, 2024UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO10% ownerSale20,315$4.21$85.5KForm 4

All 24 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 2, 2023Raised $18.3 million in a private offering of equity Form D: 15 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 59. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Voss Capital, LP5,261,921$5.5M0.3%+873,559
Cable Car Capital, LP5,195,000$5.4M0.1%+4,775,000
ADAR1 Capital Management, LLC4,500,000$4.7M0.2%New
Vanguard Capital Management LLC3,377,910$3.5M0.0%+2,379,389
BIOS Capital Management, LP2,982,375$3.1M7.4%+1,000,000
Ikarian Capital, LLC2,950,000$3.1M0.5%New
Great Point Partners LLC2,575,000$2.7M0.6%New
Citadel Advisors LLC2,438,711$2.5M0.0%New
Velan Capital Investment Management LP1,700,000$1.8M1.1%New
Senvest Management, LLC1,230,895$1.3M0.0%+1,000,000
Prosight Management, LP1,100,000$1.1M0.2%+688,400
Bleichroeder LP1,000,000$1.0M0.2%New
Boothbay Fund Management, LLC889,450$925.0K0.0%New
Geode Capital Management, LLC733,139$762.5K0.0%+388,449
University Of Texas/texas Am Investment Management Co511,610$532.1K0.1%No change
Vanguard Fiduciary Trust Co382,515$397.8K0.0%+228,003
State Street Corp379,604$394.8K0.0%+303,700
Empery Asset Management, LP370,834$385.7K0.4%New
Sigma Planning Corp353,677$367.8K0.0%+5,000
BlackRock, Inc.326,204$339.3K0.0%+257,676
Texas Capital Bank Wealth Management Services Inc300,758$312.8K0.0%+27,133
Sequoia Financial Advisors, LLC250,000$260.0K0.0%New
Gagnon Securities LLC229,070$238.2K0.0%−10,450
Stonepine Capital Management, LLC218,038$226.8K0.2%New
Palogic Value Management, L.P.180,000$187.2K0.1%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53